FI120238B - Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi - Google Patents
Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi Download PDFInfo
- Publication number
- FI120238B FI120238B FI971100A FI971100A FI120238B FI 120238 B FI120238 B FI 120238B FI 971100 A FI971100 A FI 971100A FI 971100 A FI971100 A FI 971100A FI 120238 B FI120238 B FI 120238B
- Authority
- FI
- Finland
- Prior art keywords
- plasmid
- nucleic acid
- acid sequence
- afgf
- protein
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 92
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 30
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 25
- 241000701867 Enterobacteria phage T7 Species 0.000 claims abstract description 23
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 42
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000013613 expression plasmid Substances 0.000 claims description 13
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 5
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 102000007592 Apolipoproteins Human genes 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000001039 Dystrophin Human genes 0.000 claims description 2
- 108010069091 Dystrophin Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000001228 trophic effect Effects 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 229930027917 kanamycin Natural products 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000006142 Luria-Bertani Agar Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000002306 biochemical method Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 101150068959 parD gene Proteins 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- 102100037320 Apolipoprotein A-IV Human genes 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 101100489581 Caenorhabditis elegans par-5 gene Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 1
- 101100284207 Escherichia coli (strain K12) gyrA gene Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004038 Glia Maturation Factor Human genes 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000034452 Methionyl aminopeptidases Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 101100385662 Mus musculus Cul9 gene Proteins 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 231100000704 bioconcentration Toxicity 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- -1 etc. Proteins 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 101150004979 flmA gene Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 101150048892 parB gene Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9411049A FR2724665B1 (fr) | 1994-09-16 | 1994-09-16 | Procede de production de proteines recombinantes, plasmides et cellules modifiees |
FR9411049 | 1994-09-16 | ||
PCT/FR1995/001178 WO1996008572A1 (fr) | 1994-09-16 | 1995-09-14 | Procede de production de proteines recombinantes, plasmides et cellules modifiees |
FR9501178 | 1995-09-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI971100A FI971100A (fi) | 1997-03-14 |
FI971100A0 FI971100A0 (fi) | 1997-03-14 |
FI120238B true FI120238B (fi) | 2009-08-14 |
Family
ID=9466987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI971100A FI120238B (fi) | 1994-09-16 | 1997-03-14 | Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi |
Country Status (19)
Country | Link |
---|---|
US (1) | US6143518A (de) |
EP (1) | EP0781341B1 (de) |
JP (1) | JP3696247B2 (de) |
KR (1) | KR100391752B1 (de) |
AT (1) | ATE405656T1 (de) |
AU (1) | AU708080B2 (de) |
CA (1) | CA2197804C (de) |
DE (1) | DE69535815D1 (de) |
DK (1) | DK0781341T3 (de) |
ES (1) | ES2313721T3 (de) |
FI (1) | FI120238B (de) |
FR (1) | FR2724665B1 (de) |
IL (1) | IL115308A (de) |
MX (1) | MX9701614A (de) |
NO (1) | NO320374B1 (de) |
PT (1) | PT781341E (de) |
TW (1) | TW517086B (de) |
WO (1) | WO1996008572A1 (de) |
ZA (1) | ZA957750B (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9618001D0 (en) * | 1996-08-29 | 1996-10-09 | Nyfotek As | Novel expression vectors |
US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
EP0998945A1 (de) * | 1998-09-30 | 2000-05-10 | Transgene S.A. | Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie |
EP1022337B1 (de) * | 1999-01-20 | 2006-07-26 | Bayer HealthCare AG | Plasmide, deren Konstruktion und deren Verwendung zur Herstellung von Interleukin-4 und Interleukin-4 Muteine |
DE69929638T2 (de) | 1999-01-20 | 2006-09-21 | Bayer Healthcare Ag | Plasmide, deren Konstruktion und Anwendung zur Herstellung von Interleukin-4 und dessen Muteine |
MXPA02003885A (es) * | 1999-10-19 | 2005-06-03 | Bharat Biotech International L | Expresion de lisostafina madura recombinante. |
US9051589B2 (en) * | 2005-10-27 | 2015-06-09 | Kaneka Corporation | Plasmid vector and transformant stably retaining plasmid |
JP5650368B2 (ja) * | 2005-10-27 | 2015-01-07 | 株式会社カネカ | 新規プラスミドベクター及びプラスミドを安定に保持する形質転換体 |
NZ588895A (en) | 2008-05-13 | 2012-07-27 | Clarassance Inc | Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis |
US9168285B2 (en) | 2009-10-15 | 2015-10-27 | Therabron Therapeutics, Inc. | Recombinant human CC10 protein for treatment of influenza and ebola |
KR101597391B1 (ko) | 2009-10-15 | 2016-02-24 | 클라라산스, 인크. | 인플루엔자 치료용 재조합 사람 cc10 단백질 |
BR102014014502B1 (pt) * | 2014-06-13 | 2020-09-15 | Ouro Fino Saúde Animal Ltda | Vetor de expressão |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK410783D0 (da) * | 1982-09-16 | 1983-09-09 | Benzon A Salfred | Fremgangsmade til stabilisering af plasmider |
DE3247922A1 (de) * | 1982-12-24 | 1984-06-28 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten |
NZ220917A (en) * | 1986-07-11 | 1991-05-28 | Merck & Co Inc | Human and bovine acidic fibroblast growth factor vectors, hosts and compositions |
US5175147A (en) * | 1988-08-19 | 1992-12-29 | Takeda Chemical Industries, Ltd | Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract |
FR2642086B1 (fr) * | 1989-01-26 | 1992-09-04 | Sanofi Sa | Gene recombinant codant pour un facteur basique de croissance des fibroblastes et ledit facteur |
EP0406738A3 (en) * | 1989-07-03 | 1991-08-14 | Takeda Chemical Industries, Ltd. | Production of acidic fgf protein |
FR2661188B1 (fr) * | 1990-04-24 | 1994-07-22 | Rhone Poulenc Sante | Nouveaux vecteurs de clonage et/ou d'expression, procede de preparation et leur utilisation. |
-
1994
- 1994-09-16 FR FR9411049A patent/FR2724665B1/fr not_active Expired - Lifetime
-
1995
- 1995-09-14 EP EP95931242A patent/EP0781341B1/de not_active Expired - Lifetime
- 1995-09-14 DK DK95931242T patent/DK0781341T3/da active
- 1995-09-14 MX MX9701614A patent/MX9701614A/es unknown
- 1995-09-14 WO PCT/FR1995/001178 patent/WO1996008572A1/fr active IP Right Grant
- 1995-09-14 AU AU34754/95A patent/AU708080B2/en not_active Expired
- 1995-09-14 IL IL115308A patent/IL115308A/en not_active IP Right Cessation
- 1995-09-14 CA CA2197804A patent/CA2197804C/fr not_active Expired - Fee Related
- 1995-09-14 KR KR1019970701694A patent/KR100391752B1/ko active IP Right Grant
- 1995-09-14 PT PT95931242T patent/PT781341E/pt unknown
- 1995-09-14 ZA ZA957750A patent/ZA957750B/xx unknown
- 1995-09-14 JP JP50995996A patent/JP3696247B2/ja not_active Expired - Fee Related
- 1995-09-14 DE DE69535815T patent/DE69535815D1/de not_active Expired - Lifetime
- 1995-09-14 ES ES95931242T patent/ES2313721T3/es not_active Expired - Lifetime
- 1995-09-14 US US08/793,900 patent/US6143518A/en not_active Expired - Lifetime
- 1995-09-14 AT AT95931242T patent/ATE405656T1/de active
- 1995-09-16 TW TW084109710A patent/TW517086B/zh not_active IP Right Cessation
-
1997
- 1997-03-12 NO NO19971139A patent/NO320374B1/no not_active IP Right Cessation
- 1997-03-14 FI FI971100A patent/FI120238B/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPH10505746A (ja) | 1998-06-09 |
ZA957750B (en) | 1996-04-24 |
NO971139L (no) | 1997-03-12 |
DK0781341T3 (da) | 2009-01-05 |
ATE405656T1 (de) | 2008-09-15 |
FI971100A (fi) | 1997-03-14 |
JP3696247B2 (ja) | 2005-09-14 |
AU3475495A (en) | 1996-03-29 |
US6143518A (en) | 2000-11-07 |
PT781341E (pt) | 2008-11-20 |
AU708080B2 (en) | 1999-07-29 |
CA2197804C (fr) | 2010-11-16 |
TW517086B (en) | 2003-01-11 |
NO320374B1 (no) | 2005-11-28 |
KR100391752B1 (ko) | 2003-10-22 |
MX9701614A (es) | 1997-06-28 |
ES2313721T3 (es) | 2009-03-01 |
FR2724665A1 (fr) | 1996-03-22 |
CA2197804A1 (fr) | 1996-03-21 |
IL115308A (en) | 2009-07-20 |
EP0781341A1 (de) | 1997-07-02 |
WO1996008572A1 (fr) | 1996-03-21 |
FR2724665B1 (fr) | 1996-12-20 |
EP0781341B1 (de) | 2008-08-20 |
NO971139D0 (no) | 1997-03-12 |
DE69535815D1 (de) | 2008-10-02 |
FI971100A0 (fi) | 1997-03-14 |
IL115308A0 (en) | 1995-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6291245B1 (en) | Host-vector system | |
FI120238B (fi) | Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi | |
Winans | Transcriptional induction of an Agrobacterium regulatory gene at tandem promoters by plant-released phenolic compounds, phosphate starvation, and acidic growth media | |
Plamann et al. | Nucleotide sequence of the Salmonella typhimurium metR gene and the metR-metE control region | |
CA2294760C (en) | Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin | |
MXPA97001614A (en) | Procedure for the production of recombinant proteins, plasmids and cells modifies | |
KR19990044525A (ko) | 플라스미드의 안정화 | |
Zimmer et al. | Temperature tolerance of hydrogenase expression in Alcaligenes eutrophus is conferred by a single amino acid exchange in the transcriptional activator HoxA | |
CA2176236C (en) | Tyrosinase-activator protein fusion enzyme | |
KR102282778B1 (ko) | 재조합 미생물 및 이의 사용 방법 | |
US20130189757A1 (en) | Affinity purification of rna under native conditions based on the lambda boxb/n peptide interaction | |
CN112513066A (zh) | Crm197蛋白质表达 | |
WO2011086447A2 (en) | Fermentation process for the preparation of recombinant heterologous proteins | |
CN108410901B (zh) | 无抗性筛选双抗原锚定表达载体pLQ2a及制备方法 | |
EP0141362A2 (de) | Plasmid-Vektor | |
US11970700B1 (en) | Genetic element E3 for enhanced intracellular expression of target protein encoded in RNA therapeutics | |
US8628954B2 (en) | Expression cassette, use of the expression cassette, vector, host cell, a method for producing a polypeptide | |
ES2257853T3 (es) | Construcciones para la expresion controlada de genes recombinantes en celulas procariotas. | |
EP0336413B1 (de) | System der induzierbaren positiven Regulation zur Verwendung für die Herstellung von heterologen Proteinen | |
SU1730151A1 (ru) | Рекомбинантна плазмидна ДНК р 9 F МД, кодирующа гибридный полипептид Р199 - ASp PRo CYS CYS - VP1 /200 - 213/ - PRo PRo SeR PRo - Vp1 /131 - 152/ PRo CYS GLY и штамм бактерий ЕSснеRIснIа coLI продуцент гибридного полипептида Р199 - ASp PRo CYS GLY - VP1 /200 - 213/ PRo PRo SeR PRo - VP1 /131 - 152/ - PRo CYS GLY | |
CN116323680A (zh) | 肽标签和包含其的附加有标签的蛋白 | |
Zouine et al. | Overproduction, purification and characterization of the HPB12-L24 ribosomal protein of Bacillus subtilis | |
CN116406370A (zh) | 肽标签和包含其的附加有标签的蛋白 | |
CN110511951A (zh) | Plb蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用 | |
MXPA00010057A (en) | Novel constructs for controlled expression of recombinant proteins in prokaryotic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: AVENTIS PHARMA S.A. |
|
FG | Patent granted |
Ref document number: 120238 Country of ref document: FI |
|
MM | Patent lapsed |